<DOC>
	<DOCNO>NCT02933710</DOCNO>
	<brief_summary>The purpose study perform re-examination IMOJEV® routine clinical setting accordance Ministry Food Drug Safety regulation . Primary objective : - To describe safety profile first dose IMOJEV® administer routine health care visit primary vaccination booster .</brief_summary>
	<brief_title>Postmarketing Surveillance Study IMOJEV® Republic Korea</brief_title>
	<detailed_description>Subjects age 12 month age old give study vaccine routine health-care visit enrol study . They also receive one dose booster 12 24 month primary dose . No study vaccine supply administer part study , subject monitor follow routine vaccine administration clinical setting .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Informed consent form sign subject ( subject 19 year old ) parent ( ) legal representative ( subject 19 year age ) Receipt first dose IMOJEV® ( day inclusion ) accord approve local insert paper . Participation time study enrollment ( 4 week precede study vaccination ) plan participation present study period another clinical study investigate vaccine , drug , medical device , medical procedure . Subjects already participate study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Japanese encephalitis</keyword>
	<keyword>IMOJEV®</keyword>
	<keyword>Japanese encephalitis chimeric virus vaccine</keyword>
</DOC>